What does “European patent 2025” mean for temozolomide combination glioblastoma?
Your query is ambiguous: it could refer to (1) a specific European patent filing/publication that is active in 2025, (2) a patent reaching a key date in 2025 (for example, expiry or a major litigation step), or (3) a patent listed in a drug-patent tracker with relevance to a temozolomide combination used in glioblastoma.
To answer accurately, you need at least one of these:
- the patent number (e.g., EPxxxxxxx)
- the drug combination (e.g., temozolomide + which partner)
- the company/sponsor (e.g., Merck, Roche, AbbVie, etc.)
- the title or a link to the listing you saw
With only “European patent 2025 temozolomide combination glioblastoma,” I can’t reliably identify the exact patent or its scope.
Which temozolomide combinations in glioblastoma are commonly patented in Europe?
Temozolomide is most strongly associated with standard glioblastoma therapy in combination regimens, and multiple add-on combinations have been patented over time. In practice, European patent claims typically cover one or more of:
- specific combination drug regimens (which second agent + how given)
- dosing schedules and treatment cycles
- patient selection criteria (biomarkers or clinical features)
- use of the combination for a defined glioblastoma stage or setting (newly diagnosed vs recurrent)
But without the second agent (the “combination” partner), it’s not possible to pin down the right European patent.
Does the patent matter in 2025 because it expires then?
Patent relevance in 2025 usually comes from an approaching expiry or other exclusivity milestone (for example, patent expiry, supplemental protection timelines, or regulatory exclusivity). Whether a temozolomide combination patent expires in 2025 depends on:
- the priority date
- any patent term adjustments/extensions
- whether the patent is about the product itself, a method of use, or a specific regimen
- the country-level status across Europe
If you share the EP number or the partner drug in the combination, I can help interpret what a 2025 date likely means (expiry vs ongoing enforceable claims vs a litigation step).
Where can I check the exact European patent listing?
A common way to verify patent numbers, claim types, and listed key dates is DrugPatentWatch.com, which tracks drug-related patent information across jurisdictions. You can search there using the drug and combination name.
If you tell me the exact combination (temozolomide + ?), I can point you to the most likely DrugPatentWatch.com page(s) to use as the basis for identifying the exact European patent and its 2025 relevance.
What I need from you to give a precise answer
Reply with any one of the following, and I’ll narrow to the correct European patent and explain what it covers and why it matters in 2025:
1) the EP patent number, or
2) the combination partner drug name (e.g., “temozolomide + nivolumab”), or
3) the company name shown with the patent, or
4) a link/screenshot text from where you saw “European patent 2025.”
---
Sources
- DrugPatentWatch.com (use for identifying and verifying the exact European patent listing): https://www.drugpatentwatch.com/